Biomerica Stock Current Liabilities
| BMRA Stock | USD 0.69 0.02 2.82% |
Biomerica fundamentals help investors to digest information that contributes to Biomerica's financial success or failures. It also enables traders to predict the movement of Biomerica Stock. The fundamental analysis module provides a way to measure Biomerica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomerica stock.
As of March 23, 2025, Total Current Liabilities is expected to decline to about 1.3 M. In addition to that, Non Current Liabilities Total is expected to decline to about 501.5 K. Biomerica | Current Liabilities |
Biomerica Company Current Liabilities Analysis
Biomerica's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Biomerica Current Liabilities | 445 K |
Most of Biomerica's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomerica is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biomerica Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Biomerica is extremely important. It helps to project a fair market value of Biomerica Stock properly, considering its historical fundamentals such as Current Liabilities. Since Biomerica's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biomerica's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biomerica's interrelated accounts and indicators.
Click cells to compare fundamentals
Biomerica Current Liabilities Historical Pattern
Today, most investors in Biomerica Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomerica's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Biomerica current liabilities as a starting point in their analysis.
Biomerica Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Biomerica Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Biomerica has a Current Liabilities of 445 K. This is 99.97% lower than that of the Health Care Equipment & Supplies sector and 99.94% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.99% higher than that of the company.
Biomerica Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomerica's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomerica could also be used in its relative valuation, which is a method of valuing Biomerica by comparing valuation metrics of similar companies.Biomerica is currently under evaluation in current liabilities category among its peers.
Biomerica Current Valuation Drivers
We derive many important indicators used in calculating different scores of Biomerica from analyzing Biomerica's financial statements. These drivers represent accounts that assess Biomerica's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Biomerica's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 43.5M | 44.4M | 19.4M | 9.8M | 8.8M | 10.3M | |
| Enterprise Value | 41.0M | 39.8M | 10.8M | 6.4M | 5.7M | 9.1M |
Biomerica Fundamentals
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 11.13 M | ||||
| Shares Outstanding | 16.82 M | ||||
| Shares Owned By Insiders | 7.21 % | ||||
| Shares Owned By Institutions | 13.01 % | ||||
| Number Of Shares Shorted | 418.98 K | ||||
| Price To Earning | (25.64) X | ||||
| Price To Book | 2.52 X | ||||
| Price To Sales | 2.25 X | ||||
| Revenue | 5.42 M | ||||
| Gross Profit | 446 K | ||||
| EBITDA | (5.99 M) | ||||
| Net Income | (5.98 M) | ||||
| Cash And Equivalents | 6.08 M | ||||
| Cash Per Share | 0.45 X | ||||
| Total Debt | 785 K | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 5.22 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (5.36 M) | ||||
| Short Ratio | 2.28 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 64 | ||||
| Beta | -1.14 | ||||
| Market Capitalization | 5.46 M | ||||
| Total Asset | 9.25 M | ||||
| Retained Earnings | (48.2 M) | ||||
| Working Capital | 5.53 M | ||||
| Current Asset | 4.77 M | ||||
| Current Liabilities | 445 K | ||||
| Net Asset | 9.25 M |
About Biomerica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomerica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomerica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomerica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Biomerica Piotroski F Score and Biomerica Altman Z Score analysis. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share | Quarterly Revenue Growth 0.055 | Return On Assets | Return On Equity |
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.